GRI Bio (GRI)

GRI Bio’s lead programme is GRI-0621, an oral small-molecule candidate designed as a dual agonist of retinoic acid receptor beta and gamma. The company is evaluating the compound for its ability to inhibit human type 1 NKT cell activity and help restore immune homeostasis. The active approach is related to tazarotene, a synthetic retinoid best known for dermatology uses such as psoriasis and acne, but GRI Bio is pursuing systemic applications in diseases where immune-driven inflammation and fibrosis are central features.

The company is also advancing GRI-0803, an oral candidate intended to activate type 2 NKT cells. This programme is aimed at autoimmune disorders and reflects GRI Bio’s broader interest in selectively adjusting immune pathways rather than broadly suppressing immunity. As a development-stage biotech, GRI Bio’s value is closely tied to preclinical and clinical progress, regulatory milestones, safety data, and its ability to secure capital or partnerships. Investors typically view the stock as a high-risk life sciences exposure, with potential upside linked to successful validation of its NKT cell-focused platform.